BookR: School of Health Core Facilities Booking
PubMed Publications| Keyword search (4,163 papers available) |  |
"Rosa-Neto P" Authored Publications:
| Title | Authors | PubMed ID | |
|---|---|---|---|
| 1 | Associations between brain and cognitive resilience, tau load and extent in Alzheimer's disease | Mitchell SW; Chan T; Trudel L; Hosseini SA; Macedo AC; Gonçalves MP; Rahmouni N; Hall BJ; Socualaya KMQ; Therriault J; Servaes S; Bezgin G; Zheng Y; Aumont E; Wang YT; Arias JF; Real APB; Jia WL; Hopewell R; Hsiao C; Soucy JP; Vitali P; Pascoal TA; Rosa-Neto P; | 41512332 PERFORM |
| 2 | Alzheimer s Imaging Consortium | Mitchell SW; Chan T; Trudel L; Hosseini SA; Macedo AC; Gonçalves MP; Rahmouni N; Hall BJ; Socualaya KMQ; Therriault J; Servaes S; Bezgin G; Zheng Y; Aumont E; Wang YT; Arias JF; Real APB; Jia WL; Hopewell R; Hsiao C; Soucy JP; Vitali P; Pascoal TA; Rosa-Neto P; | 41433447 PERFORM |
| 3 | Peripheral inflammation in a Canadian cohort of neurodegenerative conditions: Occurrence, determinants, and impact | Seixas-Lima B; Rosa-Neto P; Phillips NA; Borrie M; Roncero CT; Lahiri D; Dori D; Eintracht S; Chertkow H; | 41358624 PSYCHOLOGY |
| 4 | The PREVENT-AD cohort: Accelerating Alzheimer s disease research and treatment in Canada and beyond | Villeneuve S; Poirier J; Breitner JCS; Tremblay-Mercier J; Remz J; Raoult JM; Yakoub Y; Gallego-Rudolf J; Qiu T; Fajardo Valdez A; Mohammediyan B; Javanray M; Metz A; Sanami S; Ourry V; Wearn A; Pastor-Bernier A; Edde M; Gonneaud J; Strikwerda-Brown C; Tardif CL; Gauthier CJ; Descoteaux M; Dadar M; Vachon-Presseau É; Baril AA; Ducharme S; Montembeault M; Geddes MR; Soucy JP; Rajah N; Laforce R; Bocti C; Davatzikos C; Bellec L; Rosa-Neto P; Baillet S; Evans AC; Collins DL; Chakravarty MM; Blennow K; Zetterbe | 41020412 SOH |
| 5 | The PREVENT-AD cohort: accelerating Alzheimer s disease research and treatment in Canada and beyond | Villeneuve S; Poirier J; Breitner JCS; Tremblay-Mercier J; Remz J; Raoult JM; Yakoub Y; Gallego-Rudolf J; Qiu T; Valdez AF; Mohammediyan B; Javanray M; Metz A; Sanami S; Ourry V; Wearn A; Pastor-Bernier A; Edde M; Gonneaud J; Strikwerda-Brown C; Tardif CL; Gauthier CJ; Descoteaux M; Dadar M; Vachon-Presseau É; Baril AA; Ducharme S; Montembeault M; Geddes MR; Soucy JP; Rajah N; Laforce R; Bocti C; Davatzikos C; Bellec L; Rosa-Neto P; Baillet S; Evans AC; Collins DL; Chakravarty MM; Blennow K; Zetterberg H; S | 40778177 PSYCHOLOGY |
| 6 | Use of lecanemab and donanemab in the Canadian healthcare system: Evidence, challenges, and areas for future research | Smith EE; Phillips NA; Feldman HH; Borrie M; Ganesh A; Henri-Bhargava A; Desmarais P; Frank A; Badhwar A; Barlow L; Bartha R; Best S; Bethell J; Bhangu J; Black SE; Bocti C; Bronskill SE; Burhan AM; Calon F; Camicioli R; Campbell B; Collins DL; Dadar M; DeMarco ML; Ducharme S; Duchesne S; Einstein G; Fisk JD; Gawryluk JR; Grossman L; Ismail Z; Itzhak I; Joshi M; Harrison A; Kroger E; Kumar S; Laforce R; Lanctot KL; Lau M; Lee L; Masellis M; Massoud F; Mitchell SB; Montero-Odasso M; Myers Barnett K; Nygaard HB; Pasternak SH; Peters J; Rajah MN; Robillard JM; Rockwood K; Rosa-Neto P; Seitz DP; Soucy JP; Trenaman SC; Wellington CL; Zadem A; Chertkow H; | 39893139 CONCORDIA |
| 7 | Alzheimer's Imaging Consortium | Soucy JP; Belasso CJ; Cai Z; Bezgin G; Stevenson J; Rahmouni N; Tissot C; Lussier FZ; Rosa-Neto P; Rivaz HJ; Benali H; | 39782975 CONCORDIA |
| 8 | Biomarkers | Soucy JP; Belasso CJ; Cai Z; Bezgin G; Stevenson J; Rahmouni N; Tissot C; Lussier FZ; Rosa-Neto P; Rivaz HJ; Benali H; | 39784152 CONCORDIA |
| 9 | Basic Science and Pathogenesis | Lima BS; Rosa-Neto P; Phillips N; Borrie M; Roncero CT; Lahiri D; Dori D; Chertkow H; | 39751468 CONCORDIA |
| 10 | Impact of a national dementia research consortium: The Canadian Consortium on Neurodegeneration in Aging (CCNA) | Chertkow H; Phillips N; Rockwood K; Anderson N; Andrew MK; Bartha R; Beaudoin C; Bélanger N; Bellec P; Belleville S; Bergman H; Best S; Bethell J; Bherer L; Black S; Borrie M; Camicioli R; Carrier J; Cashman N; Chan S; Crowshoe L; Cuello C; Cynader M; Dang-Vu T; Das S; Dixon RA; Ducharme S; Einstein G; Evans AC; Fahnestock M; Feldman H; Ferland G; Finger E; Fisk JD; Fogarty J; Fon E; Gan-Or Z; Gauthier S; Greenwood C; Henri-Bellemare C; Herrmann N; Hogan DB; Hsiung R; Itzhak I; Jacklin K; Lanctôt K; Lim A; MacKenzie I; Masellis M; Maxwell C; McAiney C; McGilton K; McLaurin J; Mihailidis A; Mohades Z; Montero-Odasso M; Morgan D; Naglie G; Nygaard H; O' Connell M; Petersen R; Pilon R; Rajah MN; Rapoport M; Roach P; Robillard JM; Rogaeva E; Rosa-Neto P; Rylett J; Sadavoy J; St George-Hyslop P; Seitz D; Smith E; Stefanovic B; Vedel I; Walker JD; Wellington C; Whitehead V; Wittich W; | 39636028 HKAP |
| 11 | Neuromodulatory subcortical nucleus integrity is associated with white matter microstructure, tauopathy and APOE status | Wearn A; Tremblay SA; Tardif CL; Leppert IR; Gauthier CJ; Baracchini G; Hughes C; Hewan P; Tremblay-Mercier J; Rosa-Neto P; Poirier J; Villeneuve S; Schmitz TW; Turner GR; Spreng RN; | 38830849 SOH |
| 12 | Mesocorticolimbic function in cocaine polydrug users: A multimodal study of drug cue reactivity and cognitive regulation | Scala SG; Kang MS; Cox SML; Rosa-Neto P; Massarweh G; Leyton M; | 38221806 CSBN |
| 13 | Brain PET Imaging in Small Animals: Tracer Formulation, Data Acquisition, Image Reconstruction, and Data Analysis | Bdair H; Kang MS; Ottoy J; Aliaga A; Kunach P; Singleton TA; Blinder S; Soucy JP; Leyton M; Rosa-Neto P; Kostikov A; | 38006502 PERFORM |
| 14 | Bayesian workflow for the investigation of hierarchical classification models from tau-PET and structural MRI data across the Alzheimer's disease spectrum | Belasso CJ; Cai Z; Bezgin G; Pascoal T; Stevenson J; Rahmouni N; Tissot C; Lussier F; Rosa-Neto P; Soucy JP; Rivaz H; Benali H; | 37920382 PERFORM |
| 15 | Radiosynthesis and In Vivo Evaluation of Four Positron Emission Tomography Tracer Candidates for Imaging of Melatonin Receptors | Bdair H; Singleton TA; Ross K; Jolly D; Kang MS; Aliaga A; Tuznik M; Kaur T; Yous S; Soucy JP; Massarweh G; Scott PJH; Koeppe R; Spadoni G; Bedini A; Rudko DA; Gobbi G; Benkelfat C; Rosa-Neto P; Brooks AF; Kostikov A; | 35420022 PERFORM |
| 16 | Normal cognition in Parkinson's disease may involve hippocampal cholinergic compensation: An exploratory PET imaging study with [(18)F]-FEOBV | Legault-Denis C; Aghourian M; Soucy JP; Rosa-Neto P; Dagher A; Aumont E; Wickens R; Bedard MA; | 34628195 PERFORM |
| 17 | CCCDTD5: Clinical role of neuroimaging and liquid biomarkers in patients with cognitive impairment | Brisson M; Brodeur C; Létourneau-Guillon L; Masellis M; Stoessl J; Tamm A; Zukotynski K; Ismail Z; Gauthier S; Rosa-Neto P; Soucy JP; | 33532543 PERFORM |
| 18 | Large-scale mGluR5 network abnormalities linked to epilepsy duration in focal cortical dysplasia. | DuBois JM, Mathotaarachchi S, Rousset OG, Sziklas V, Sepulcre J, Guiot MC, Hall JA, Massarweh G, Soucy JP, Rosa-Neto P, Kobayashi E | 33401137 PERFORM |
| 19 | Recommendations of the 5th Canadian Consensus Conference on the diagnosis and treatment of dementia. | Ismail Z, Black SE, Camicioli R, Chertkow H, Herrmann N, Laforce R, Montero-Odasso M, Rockwood K, Rosa-Neto P, Seitz D, Sivananthan S, Smith EE, Soucy JP, Vedel I, Gauthier S, CCCDTD5 participants | 32725777 PERFORM |
| 20 | Topographical distribution of Aβ predicts progression to dementia in Aβ positive mild cognitive impairment | Pascoal TA, Therriault J, Mathotaarachchi S, Kang MS, Shin M, Benedet AL, Chamoun M, Tissot C, Lussier F, Mohaddes S, Soucy JP, Massarweh G, Gauthier S, Rosa-Neto P, | 32582834 PERFORM |
| 21 | Metabotropic glutamate type 5 receptor binding availability during dextroamphetamine sensitization in mice and humans. | Smart K, Nagano-Saito A, Milella MS, Sakae DY, Favier M, Vigneault E, Louie L, Hamilton A, Ferguson SSG, Rosa-Neto P, Narayanan S, El Mestikawy S, Leyton M, Benkelfat C | 32559027 CSBN |
| 22 | Non-invasive in vivo hyperspectral imaging of the retina for potential biomarker use in Alzheimer's disease. | Hadoux X, Hui F, Lim JKH, Masters CL, Pébay A, Chevalier S, Ha J, Loi S, Fowler CJ, Rowe C, Villemagne VL, Taylor EN, Fluke C, Soucy JP, Lesage F, Sylvestre JP, Rosa-Neto P, Mathotaarachchi S, Gauthier S, Nasreddine ZS, Arbour JD, Rhéaume MA, Beaulieu S, Dirani M, Nguyen CTO, Bui BV, Williamson R, Crowston JG, van Wijngaarden P | 31530809 PERFORM |
| 23 | Inferior Longitudinal Fasciculus' Role in Visual Processing and Language Comprehension: A Combined MEG-DTI Study. | Shin J, Rowley J, Chowdhury R, Jolicoeur P, Klein D, Grova C, Rosa-Neto P, Kobayashi E | 31507359 PERFORM |
| 24 | Metabotropic Glutamate Receptor Type 5 (mGluR5) Cortical Abnormalities in Focal Cortical Dysplasia Identified In Vivo With [11C]ABP688 Positron-Emission Tomography (PET) Imaging. | DuBois JM, Rousset OG, Guiot MC, Hall JA, Reader AJ, Soucy JP, Rosa-Neto P, Kobayashi E | 27578494 PERFORM |
| 25 | Quantification of brain cholinergic denervation in Alzheimer's disease using PET imaging with [18F]-FEOBV. | Aghourian M, Legault-Denis C, Soucy JP, Rosa-Neto P, Gauthier S, Kostikov A, Gravel P, Bédard MA | 28894304 PERFORM |
| 26 | Amyloid and tau signatures of brain metabolic decline in preclinical Alzheimer's disease. | Pascoal TA, Mathotaarachchi S, Shin M, Park AY, Mohades S, Benedet AL, Kang MS, Massarweh G, Soucy JP, Gauthier S, Rosa-Neto P, Alzheimer’s Disease Neuroimaging Initiative | 29396637 PERFORM |
| Title: | Impact of a national dementia research consortium: The Canadian Consortium on Neurodegeneration in Aging (CCNA) | ||||
| Authors: | Chertkow H, Phillips N, Rockwood K, Anderson N, Andrew MK, Bartha R, Beaudoin C, Bélanger N, Bellec P, Belleville S, Bergman H, Best S, Bethell J, Bherer L, Black S, Borrie M, Camicioli R, Carrier J, Cashman N, Chan S, Crowshoe L, Cuello C, Cynader M, Dang-Vu T, Das S, Dixon RA, Ducharme S, Einstein G, Evans AC, Fahnestock M, Feldman H, Ferland G, Finger E, Fisk JD, Fogarty J, Fon E, Gan-Or Z, Gauthier S, Greenwood C, Henri-Bellemare C, Herrmann N, Hogan DB, Hsiung R, Itzhak I, Jacklin K, Lanctôt K, Lim A, MacKenzie I, Masellis M, Maxwell C, McAiney C, McGilton K, McLaurin J, Mihailidis A, Mohades Z, Montero-Odasso M, Morgan D, Naglie G, Nygaard H, O', Connell M, Petersen R, Pilon R, Rajah MN, Rapoport M, Roach P, Robillard JM, Rogaeva E, Rosa-Neto P, Rylett J, Sadavoy J, St George-Hyslop P, Seitz D, Smith E, Stefanovic B, Vedel I, Walker JD, Wellington C, Whitehead V, Wittich W | ||||
| Link: | https://pubmed.ncbi.nlm.nih.gov/39636028/ | ||||
| DOI: | 10.1177/13872877241290990 | ||||
| Publication: | Journal of Alzheimer s disease : JAD | ||||
| Keywords: | Alzheimer'; s disease; cohort; dementia; prevention; research plan; sex; synergy; | ||||
| PMID: | 39636028 | Category: | Date Added: | 2024-12-05 | |
| Dept Affiliation: |
HKAP
1 Lady Davis Institute for Medical Research, Montréal, Québec, Canada. 2 Department of Medicine (Neurology), University of Toronto, Toronto, Ontario, Canada. 3 Rotman Research Institute, Baycrest Academy for Research & Education, Toronto, Ontario, Canada. 4 Affiliate Member, Department of Neurology and Neurosurgery, McGill University, Montréal, Québec, Canada. 5 Department of Psychology, Concordia University, Montréal, Québec, Canada. 6 Division of Geriatric Medicine, Department of Medicine, Dalhousie University, Halifax, Nova Scotia, Canada. 7 Department of Psychology, University of Toronto, Toronto, Ontario, Canada. 8 Division of Geriatric Medicine, Department of Community Health and Epidemiology, Dalhousie University, Halifax, Nova Scotia, Canada. 9 Department of Psychiatry, University of Western Ontario, London, Ontario, Canada. 10 The Brain and Mind Institute, University of Western Ontario, London, Ontario, Canada. 11 McGill Centre for Integrative Neuroscience, Montréal, Québec, Canada. 12 Centre de recherche IUGM, Institut universitaire de gériatrie de Montréal, Montréal, Québec, Canada. 13 Département de psychologie, Université de Montréal, Montréal, Québec, Canada. 14 Department of Medicine (Geriatrics) and Oncology, McGill University, Montréal, Québec, Canada. 15 Department of Family Medicine, McGill University, Montréal, Québec, Canada. 16 Lawson Health Research Institute, London, Ontario, Canada. 17 KITE-Toronto Rehabilitation Institute, University Health Network, Toronto, Canada. 18 Département de médecine, Université de Montréal, Montréal, Québec, Canada. 19 Institut de Cardiologie de Montréal-Montreal Heart Institute, Montréal, Québec, Canada. 20 Sunnybrook Research Institute, Toronto, Ontario, Canada. 21 Department of Medicine (Neurology), University of Toronto, Toronto, Ontario, Canada; Sunnybrook Research Institute, Toronto, Ontario, Canada. 22 Schulich School of Medicine & Dentistry, Department of Medicine and Division of Geriatric Medicine, University of Western Ontario, London, Ontario, Canada. 23 Schulich School of Medicine & Dentistry, Department of Medicine and Division of Geriatric Medicine, University of Western Ontario, London, Ontario, Canada; Lawson Health Research Institute, London, Ontario, Canada. 24 Department of Medicine, University of Alberta, Edmonton, Alberta, Canada. Neuroscience and Mental Health Institute, Edmonton, Alberta, Canada. 25 Department of Medicine, University of Alberta, Edmonton, Alberta, Canada. 26 Neuroscience and Mental Health Institute, Edmonton, Alberta, Canada. 27 Center for Advanced Research in Sleep Medicine (CARSM), Hôpital du Sacré-Coeur de Montréal, Montréal, Québec, Canada. 28 Division of Neurology, Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada. 29 Djavad Mowafaghian Centre for Brain Health, University of British Columbia, Vancouver, British Columbia, Canada. 30 Rotman Research Institute, Baycrest Hospital, Toronto, Ontario, Canada. 31 Department of Family Medicine & Indigenous, Local and Global Health Office, University of Calgary, Calgary, Alberta, Canada. 32 Department of Neurology and Neurosurgery, McGill University, Montréal, Qikb1uébec, Canada. 33 Department of Pharmacology & Therapeutics, McGill Univers |
||||
Description: |
The Canadian Consortium on Neurodegeneration in Aging (CCNA) was created by the Canadian federal government through its health research funding agency, the Canadian Institutes for Health Research (CIHR), in 2014, as a response to the G7 initiative to fight dementia. Two five-year funding cycles (2014-2019; 2019-2024) have occurred following peer review, and a third cycle (Phase 3) has just begun. A unique construct was mandated, consisting of 20 national teams in Phase I and 19 teams in Phase II (with research topics spanning from basic to clinical science to health resource systems) along with cross-cutting programs to support them. Responding to the needs of researchers within the CCNA teams, a unique sample of 1173 deeply phenotyped patients with various forms of dementia was accrued and studied over eight years (COMPASS-ND). In the second phase of funding (2019-2024), a national dementia prevention program (CAN-THUMBS UP) was set up. In a short time, this prevention program became a member of the World Wide FINGERS prevention consortium. In this article, the challenges, successes, and impacts of CCNA in Canada and internationally are discussed. Short-term deliverables have occurred, along with considerable promise of impacts in the longer term. The creation of synergy, networking, capacity building, engagement of people with lived experience, and economies of scale have contributed to the considerable success of CCNA by all measures. CCNA is evidence that an organized "centrally-organized" approach to dementia research can catalyze important progress nationally and yield significant and measurable results. |
